CI

At a glance

ClinicalIndex Comparison Record
N/AUnknown· 600 target
Drug / intervention
next generation sequencegenetic
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04110223
NCT04110223N/AUnknown
CompareCT.gov

Validation Studies of Biomarkers for Precision Radiation Oncology in Locally Advanced Solid Tumors

Shandong Cancer Hospital and Institute·observational·Posted Oct 1, 2019·Updated Oct 1, 2019

In Brief

An observational study evaluating next generation sequence for Radiation Toxicity and 2 related conditions. Targeting 600 participants across 1 site.

Detailed Summary

Despite the common application of radiotherapy in cancer treatment, the prediction of radiosensitivity and treatment response has not yet entered the era of precision medicine. Therefore, development of genome-based methods for predicting radiosensitivity and treatment response is a central goal of radiation oncology. In the previous study, the investigators have identified a set of novel potential biomarkers associated with radiosensitivity and recurrence，through correlating patients' genomic profiles with toxicity, disease progression and overall survival after RT.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRadiation Toxicity, Advanced Cancer, Radiosensitivity
CountriesChina
Collaborators--

Timeline

N/AUnknownOverdue
20192020202120222023202420252026
First PostedOct 1, 2019
Enrollment StartOct 8, 2018
Primary CompletionOct 8, 2021
TodayJul 1, 2026
Enrollment to primary: 3 yearsPosted 6.8 years ago

Interventions

next generation sequencegenetic

targeted NGS of patients' pretreatment tumor biopsy samples using a 474-gene panel, which covers cancer- and radio-sensitivity-related mutations and SNPs.